Floatz logo

Repotrectinib

Hepatic Impairment

Bristol-Myers SquibbSmall moleculePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Hepatic Impairment cohort.

Asset / SponsorPhaseRating
Pioglitazone
Yonsei University
Phase 4BBB
Metformin
Taipei City Hospital
Phase 4BBB
Empagliflozin
Military University Hospital, Prague
Phase 4BB
Glibenclamide
Takeda
Phase 4BB
10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one
Tanta University
Phase 4BB

View all 50 →

Same molecule, other indications

Repotrectinib is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
hormone receptor-positive breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →
invasive lobular breast carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →